Diabetic Macular Edema
A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with diabetic macular edema.
ENDURANCE IIT (NCRVA & Regeneron)
A 2 year investigator initiated study on the long-term efficacy and safety of intravitreal aflibercept (Eylea) injections for the treatment of diabetic macular edema in subjects who completed the three year VISTA-DME trial.
A 3 year, phase 4 safety study of IOP signals in patients with DME who are treated with ILUVIEN (fluocinolone acetonide intravitreal implant).
PROTOCOL U (DRCR Network)
A short-term (9 months) evaluation of combination corticosteroid (Ozurdex) + Anti-VEGF (Lucentis) Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy.
A 9 month, phase 2, randomized, double-masked study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with diabetic macular edema.
DEL MAR (Allegro)
A 6 month, phase 2, multicenter, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy of Luminate (ALG-1001) as compared to Avastin in the treatment of diabetic macular edema.
A phase 2, six month study on the evaluation of Abidipar Pegol (AGN-150998) in patients with decreased vision due to diabetic macular edema.
A double-masked, randomized, active-controlled, phase 3 study of the efficacy and safety of intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema.